Search | Clinical Trials Finder

Independent directory Public ClinicalTrials.gov records United States

ClinicalTrials.gov public records Last synced Sep 27, 2026, 3:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–14 of 14 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Intervention: Atomoxetine, then Placebo Clear all

Conditions: Attention Deficit Hyperactivity Disorder, Insomnia
Interventions: atomoxetine, placebo; Drug
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 6 Years to 17 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Alcohol-induced Cue-craving, Alcohol Sensitivity
Interventions: Placebo Comparator, Active Comparator: Atomoxetine, Placebo; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 21 Years to 45 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Charlottesville/ Richmond, Virginia

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Guanfacine hydrochloride (TAK-503), Atomoxetine hydrochloride, Placebo; Drug · Other
Lead sponsor: Shire; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 20
States / cities: Dothan, Alabama • Anaheim, California • Imperial, California + 17 more

Conditions: Alcohol Use Disorder
Interventions: Atomoxetine, Placebo; Drug
Lead sponsor: Brown University; Other
Eligibility: 14 Years to 20 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Methamphetamine Abuse, Methamphetamine Dependence
Interventions: Atomoxetine, then Placebo, Placebo, then Atomoxetine; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 50 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Mild Cognitive Impairment
Interventions: Atomoxetine, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 50 Years to 90 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Sleep Apnea
Interventions: Atomoxetine, Oxybutynin, Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years to 70 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Menopause, Cognitive Disturbances
Interventions: atomoxetine, placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Post Traumatic Stress Disorder, Attention Deficit Hyperactivity Disorder
Interventions: Atomoxetine 80 MG; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 20 Years to 60 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Methamphetamine Dependence
Interventions: Atomoxetine, placebo; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Melanocortin Obesity Syndrome, MCOS
Interventions: Atomoxetine, Placebo; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 6 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: New York, New York • Columbus, Ohio • Nashville, Tennessee

Conditions: Autism
Interventions: Atomoxetine, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 5 Years to 15 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 2
States / cities: Indianapolis, Indiana • Lexington, Massachusetts

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Atomoxetine, Sugar Pill; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 7 Years to 12 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 2
States / cities: Cincinnati, Ohio

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Atomoxetine Hydrochloride, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 502 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 20
States / cities: Irvine, California • Gainesville, Florida • Tampa, Florida + 17 more